Evaxion A/S American Depositary Share (EVAX)

Headquarters
United States
Employees
46
Market Cap
$26M

About Evaxion A/S American Depositary Share

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

SentiSense also tracks daily options readings for Evaxion A/S American Depositary Share: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

Evaxion A/S American Depositary Share stock analysis, sentiment tracking, and market intelligence on SentiSense.